NCT01931787View on ClinicalTrials.gov

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Recurrent Small Cell Lung Cancer
Interventions
DRUG

6,8-bis(benzylthio)octanoic acid

Given IV

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01931787 - CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter